HAYWARD, Calif., and FORT COLLINS, Colo. — Impax Labs has partnered with a pharmaceutical research, development, manufacturing and commercial operations company on a multiproduct agreement.
Impax Labs and Tolmar will develop, supply and distribute alternative dosage form products. The products and terms of the agreement were not disclosed; however, Impax Labs president and CEO Larry Hsu said the new agreement "represents an ideal extension of [our] initial product agreement."
"In the past two years, we have entered into four distinct partnerships for alternative dosage form products as we continue to execute our strategy of diversifying our product base," Hsu said. "Our business development activities will continue to focus on delivering growth from high-value products, technologies and businesses in complementary dosage forms."
Added Tolmar CEO Mike Duncan, "We are very pleased with this agreement. Tolmar is once again recognized as a key player in the specialty pharma space. This agreement is aligned with our long-term corporate strategy and we firmly believe that Impax is the right partner for these products."